Patrizia Ricci

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism.

Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 20, 2024

Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.

Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.

Journal: Journal of the American Heart Association

Published: November 24, 2023

Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease.

Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease.

Journal: Biochemical pharmacology

Published: August 29, 2023

Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.

Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.

Journal: Frontiers in oncology

Published: January 09, 2023

Modeling Inflammatory Bowel Disease by Intestinal Organoids.

Modeling Inflammatory Bowel Disease by Intestinal Organoids.

Journal: Recent advances in inflammation & allergy drug discovery

Published: May 27, 2022

Immunomodulatory functions of FXR.

Immunomodulatory functions of FXR.

Journal: Molecular and cellular endocrinology

Published: January 19, 2022

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.

Journal: Expert opinion on drug discovery

Published: April 14, 2021

Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.

Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids

Published: March 09, 2020

Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.

Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.

Journal: Current opinion in pharmacology

Published: January 15, 2020

The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions.

The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions.

Journal: Nutrients

Published: June 25, 2019

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.

Journal: Nutrients

Published: April 18, 2019

Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.

Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids

Published: February 25, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026